Listen to this episode on:
In this episode of Power to the Patients, Brandon Li sits down with Cosmo Feilding Mellen, CEO of Beckley Psytech, to explore the groundbreaking work Beckley is doing in the world of psychedelics. Cosmo shares his journey growing up in a family immersed in psychedelic research, co-founding Beckley Psytech, and pushing the boundaries of mental health treatment with next-generation compounds like 5-MeO-DMT.
Key topics include:
- Short-acting psychedelics: Why Beckley Psytech is interested in shorter-duration psychedelic treatments for conditions like treatment-resistant depression and substance use disorders.
- Scalability: How shorter treatments have the potential to improve scalability.
- Accessibility: Cosmo explains how their innovative approach aims to make these therapies more accessible
- Finding balance: Balancing cutting-edge science with compassionate care, while maintaining high ethical standards.
Join Brandon and Cosmo to learn about the future of psychedelics as pharmaceutical medicines, and what it takes to develop new treatments in this rapidly evolving field.
Related Podcasts
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.